Sweden · Delayed Price · Currency is SEK Guard Therapeutics International AB Company Description
Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden.
Its pipeline products include RMC-035, an intact therapeutic A1M protein, that is in Phase 2b clinical trial for kidney protection with open-heart surgery; in Phase 2a clinical trial for kidney transplantation; and is in preclinical trial to treat Sepsis.
It also develops GTZ peptides, a modified A1M-derived peptides, that is in preclinical studies for the treatment of CKD and diabetes, heart failure, alport syndrome, sickle-cell nephropathy, and preeclampsia.
The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in 2019.
Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
| Country | Sweden |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Tobias Agervald |
Contact Details
Address: Nybrogatan 34 Stockholm, 114 39 Sweden | |
| Phone | 46 86 70 65 51 |
| Website | guardtherapeutics.com |
Stock Details
| Ticker Symbol | GUARD |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0009973357 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Tobias Larsson Agervald | Chief Executive Officer |
| Karin Botha | Chief Financial Officer |
| Magnus Gram | C.S.O |
| Peter Gilmour Ph.D. | Head of Preclinical Science |
| Sara Thuresson | Head of Clinical Operations |
| Dr. Michael Reusch | Chief Medical Officer |
| Torbjorn Larsson | Head of Chemistry, Manufacturing and Controls |
| Stewart Kay | Chief Business Officer |